A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tezruly
(United States) [Available]Synonyms :
 terazosin
Class :
Antihypertensive and alpha blockers
Brand Name :
Tezruly
(United States) [Available]Synonyms :
 terazosin
Class :
Antihypertensive and alpha blockers
Dosage Forms & Strengths Â
Capsule Â
1mg Â
2mg Â
5mg Â
10mg Â
Initial:
1
mg
Orally
once a day
Dose can increase up to 5 mg- 20 mg orally once a day
Dose Adjustments
Dosing considerations:
To prevent syncope first dose and subsequent dose preferred at bedtime and can be taken with food
Initial:
1
mg
Orally
once a day
Maintenance: 1-5 mg per day for every 12hrsand can increase upto less than 20 mg per day
Dose Adjustments
Dosing considerations
To prevent syncope first dose and subsequent dose preferred at bedtime and can be taken with food
Dosage Forms & Strengths Â
Capsule Â
1mg Â
2mg Â
5mg Â
10mg Â
(Off-label) :
1
mg
Orally
once a day
increase up to 20 mg per day
may increase the hypotensive effect of anti-hypertensive agents
may increase the hypotensive effect of anti-hypertensive agents
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may have an increased hypertensive effect when combined with alpha1-blockers
may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may enhance the antihypertensive effect of other alpha1-Blockers
bunazosin (Not available in the United States)
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
it decreases the effect of hypotension on blood-lowering agents
may increase the hypotensive effect of anti-hypertensive agents
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may decrease the vasoconstriction effects
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
antihypertensive drugs may make terazosin's hypotensive effects worse
antihypertensive drugs may make terazosin's hypotensive effects worse
antihypertensive drugs may make terazosin's hypotensive effects worse
antihypertensive drugs may make terazosin's hypotensive effects worse
antihypertensive drugs may make terazosin's hypotensive effects worse
may reduce the vasoconstriction-inducing action
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
it may reduce the effect of antihypertensive agents
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
antihypertensive agents increase the efficacy of antipsychotic agents
it decreases the efficacy of antihypertensive agents
antihypertensive agents include the efficacy of duloxetine
it increases the efficacy of antihypertensive agents
it decreases the efficacy of antihypertensive agents
antihypertensive agents increase the efficacy of nitroprusside
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may decrease the constriction effects of alpha-1 agonist
may decrease the constriction effects of alpha-1 agonist
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may decrease the vasoconstriction effects of alpha/beta agonists
may increase the bradycardia effect
may increase the hypertensive effect
may increase the hypotensive effect
may increase the hypoglycaemic effect
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may increase the hypotensive effect of anti-hypertensive agents
acrivastine and pseudoephedrineÂ
may increase the vasoconstrictive effect of alpha/beta agonists
may decrease the hypertensive effect of amphetamines
may increase the hypotensive effect of calcium channel blockers
may increase the hypotensive effect of calcium channel blockers
may enhance the orthostatic effect of beta blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may decrease the vasoconstricting effect of Alpha-/Beta-Agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may decrease the vasoconstricting effect when combined with alpha1-agonists
May diminish the effects of indomethacin by pharmacodynamic antagonism
Action:Â
Terazosin is an alpha-1 adrenergic receptor blocker that works by relaxing smooth muscle in the blood vessels and the bladder neck. Its primary action is to inhibit postsynaptic alpha-1 receptors, leading to vasodilation, which helps lower blood pressure. In the urinary tract, it reduces urethral resistance and improves urine flow by relaxing the smooth muscle of the prostate and bladder neck.Â
Spectrum:Â
Terazosin is primarily used in the management of hypertension and benign prostatic hyperplasia (BPH). For hypertension, it serves as a second-line agent, helping to lower blood pressure by relaxing vascular smooth muscle. In BPH, terazosin alleviates urinary symptoms such as weak urine stream, urgency, and incomplete bladder emptying by relaxing the smooth muscles of the prostate and bladder neck, thereby improving urine flow.Â
Adverse drug reactions:  Â
Frequency defined Â
>10% Â
Dizziness Â
Asthenia  Â
1-10% Â
Sinusitis Â
Dyspnea  Â
Fatigue Â
Headache Â
Hypotension  Â
Palpitation  Â
Nausea  Â
Tachycardia Â
Amblyopia Â
Blurred vision Â
Edema Â
Back pain  Â
Flulike syndrome  Â
NoneÂ
Contraindication:Â
known hypersensitivityÂ
Caution:Â
CNS depressionÂ
Hypertensive patientsÂ
Heart failureÂ
Pregnancy warnings:    Â
US FDA pregnancy category: CÂ
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is unknownÂ
Pregnancy Categories:     Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.     Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women     Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women     Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits     Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     Â
Category N: There is no data available for the drug under this category
Terazosin is a selective alpha-1 adrenergic receptor antagonist. It works by blocking alpha-1 receptors located on vascular smooth muscle and in the prostate and bladder neck. By inhibiting these receptors, terazosin causes vasodilation, leading to a reduction in peripheral vascular resistance and, consequently, decreased blood pressure. In the lower urinary tract, it relaxes smooth muscle in the bladder neck and prostate, which helps improve urinary flow and reduce symptoms associated with benign prostatic hyperplasia (BPH).Â
Pharmacokinetics:Â
AbsorptionÂ
Terazosin is well absorbed orally, with a bioavailability of approximately 90%. For hypertension, its onset of action begins around 3 hours after dosing, while improvement in symptoms of benign prostatic hyperplasia (BPH) typically starts after about 2 weeks, with peak response observed at 4 to 6 weeks. Its effects last for about 24 hours, and peak plasma concentrations are reached within 1 hour of administration.Â
DistributionÂ
In terms of distribution, terazosin is 90–94% protein bound and has a volume of distribution ranging from 25 to 30 L.Â
Metabolism
It undergoes extensive hepatic metabolism through hydrolysis, O-demethylation, and N-dealkylation, producing metabolites such as 6- and 7-O-demethyl terazosin, a piperazine derivative, and a diamine metabolite.Â
Excretion and EliminationÂ
The elimination half-life of terazosin is between 9 and 12 hours. It is cleared renally at a rate of 9 to 12.5 mL/min, with approximately 55–60% excreted in feces and 40% eliminated through the urine.Â
Terazosin is administered orally, typically once daily at bedtime to reduce the risk of dizziness or fainting caused by a sudden drop in blood pressure (first-dose effect). The tablets should be taken whole, with or without food. Initial dosing should be low and gradually increased based on the patient’s response and tolerabilityÂ
Patient information leafletÂ
Generic Name: terazosinÂ
Pronounced: Tuh-RAY-zoh-sinÂ
Why do we use terazosin? Â
Terazosin is used in the management of both hypertension and benign prostatic hyperplasia (BPH). In patients with hypertension, it lowers blood pressure by relaxing the blood vessels, thereby improving circulation and reducing cardiovascular strain. For BPH, terazosin helps relieve urinary symptoms such as hesitancy, weak stream, urgency, and increased frequency, particularly at night, by relaxing the smooth muscle in the prostate and bladder neck to improve urine flow.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
